

News and Deals

1. Expedition Therapeutics: \$115M Series B led by General Atlantic for inflammatory respiratory disease pipeline | Aug. 5, 2026

CB Insights tracked a \$115M Series B for San Francisco-based Expedition Therapeutics, with General Atlantic leading and Adage, BVF, Forbion, Novo Holdings, RA Capital, Sanofi Ventures, Sofinnova, Venrock Healthcare Capital Partners and others participating. The company is advancing therapies for COPD and other neutrophil-driven inflammatory diseases.

HDIG take: Life-science signal: a large early-private respiratory round with a crossover-quality syndicate and direct relevance to chronic disease burden. [SOURCE](#)

2. Integrated Biosciences: \$68.37M Series A for AI-enabled small-molecule discovery in age-related disease | Aug. 5, 2026

CB Insights recorded a \$68.37M Series A for Integrated Biosciences, a San Carlos company using synthetic biology, chemistry and AI to discover therapeutics for age-related diseases. Luma Group was listed among the investors.

HDIG take: Techbio: illustrates continued investor appetite for AI-native discovery platforms tied to aging biology and chronic disease. [SOURCE](#)

3. QuantHealth: \$45M Series B led by Qumra Capital for AI clinical-trial simulation | Aug. 4, 2026

QuantHealth raised a \$45M Series B, according to CB Insights, with Qumra Capital leading and Artofin, Bertelsmann Healthcare Investments, Esplanade Ventures, GC Ventures, NewHealth Ventures, Pitango HealthTech, Sanofi Ventures and Shoni Health Ventures participating. The platform predicts patient response, enrollment and protocol performance for pharma R&D teams.

HDIG take: Clinical-trials infrastructure: improves trial design and portfolio decisions at a moment when sponsors are pushing for faster, evidence-rich development. [SOURCE](#)

4. Apella and Houston Methodist: Peer-reviewed OR studies report AI-linked capacity gains across more than 200 operating rooms | Aug. 5, 2026

Apella announced peer-reviewed studies with Houston Methodist showing a 7% increase in cardiothoracic surgical case volume and a 46 percentage-point reduction in late-ending OR days across six hospitals, without adding staff or OR resources. Houston Methodist had also joined Apella's Series B financing earlier in 2026.

HDIG take: Hospital innovation: gives health-system leaders unusually concrete evidence for ambient AI's operational ROI in perioperative care. [SOURCE](#)

5. Evotec and Odyssey Therapeutics: AI-enabled small-molecule discovery partnership in autoimmune and inflammatory disease | Aug. 6, 2026

Evotec and Odyssey Therapeutics entered an R&D collaboration under which Evotec will apply screening platforms, compound libraries and machine-learning tools to generate validated hit series across undisclosed autoimmune and inflammatory disease targets. Evotec is eligible for target-linked milestone payments; financial terms were not disclosed.

HDIG take: Biopharma partnership: pairs a platform discovery provider with a venture-backed precision-medicine company to compress early target-to-hit work. [SOURCE](#)

6. AssureCare and Curis: FQHC technology partnership targets the \$50B Rural Health Transformation program | Aug. 4, 2026

AssureCare and FQHC consultancy Curis formed a partnership to help community health centers deploy Rural Health Transformation program funding. AssureCare brings care-management, patient-engagement, AI-supported analytics and nutrition-management technology; Curis brings strategy and compliance support for health centers.

HDIG take: Provider-market relevance: positions health tech around a major federal funding stream for rural care infrastructure, population health and food-as-medicine programs. [SOURCE](#)

7. ReCode Therapeutics: Cystic Fibrosis Foundation backs latest Series B tranche for SORT LNP platform | Aug. 6, 2026

CB Insights tracked a Series B financing tranche for ReCode Therapeutics with the Cystic Fibrosis Foundation participating. ReCode is developing mRNA and gene-correction therapies using its selective organ targeting lipid nanoparticle platform for rare and genetically defined diseases.

HDIG take: Rare-disease platform: foundation participation reinforces patient-advocacy capital as a catalyst for translational genetic-medicine programs. [SOURCE](#)

8. ClonOrgan: Series A extension advances gene-edited xenotransplantation donor-pig platform | Aug. 7, 2026

Chengdu-based ClonOrgan completed a Series A-IV round, according to CB Insights, with CAS Star listed as lead and Beida Fund, Guanghe VC, Lenovo Capital and Incubator Group, WEGO and other investors participating. The company develops gene-edited donor pigs for transplantable kidneys, livers, hearts, skin and blood products.

HDIG take: Life-science frontier: xenotransplantation remains high-risk but strategically important for organ-supply constraints and transplant innovation. [SOURCE](#)

9. Cirrus Therapeutics: \$3.7M Seed for ocular immunology gene therapy targeting AMD | Aug. 4, 2026

CB Insights recorded a \$3.7M Seed financing for Cambridge-based Cirrus Therapeutics, with Cedars-Sinai Intellectual Property Company and undisclosed investors participating. Cirrus is developing gene therapies intended to modulate ocular inflammation in age-related macular degeneration.

HDIG take: TTO/startup relevance: a translational ophthalmology program emerging around university-linked IP and a large, costly chronic-disease market. [SOURCE](#)

10. Bolt Navigation: \$4.24M Series B extension for handheld spine-surgery navigation | Aug. 4, 2026

CB Insights tracked a \$4.24M Series B-II financing for Bolt Navigation, with Grand Oaks Capital and Impact Capital participating. The company develops a handheld, implant-agnostic surgical navigation system designed for minimally invasive spinal procedures and lower capital burden than room-scale navigation platforms.

HDIG take: Medtech commercialization: supports a workflow-friendly surgical navigation approach suited to hospitals and ASCs watching capital equipment spend. [SOURCE](#)

11. Consint: \$2.31M Series A for AI health-claims fraud analytics and automation | Aug. 6, 2026

Noida-based Consint raised a \$2.31M Series A, CB Insights reported, with BIG Global Investments, Equanimity Investments and Seafund participating. The company sells AI-driven fraud analytics, claims automation and health-record standardization tools to hospitals and insurers.

HDIG take: Revenue integrity: payer-provider administrative AI remains a pragmatic near-term deployment area with clear cost-containment pressure. [SOURCE](#)

Upcoming Healthcare Events

Date	Event	Location	Why it matters
Aug. 27, 2026	Border Health Innovation Summit	El Paso, TX	Regional health-innovation summit hosted by the Medical Center of the Americas, focused on research, medical practice, technology development, talent creation and investment across the border health ecosystem.
Aug. 27, 2026	Semiconductor-MedTech Ecosystem Summit	Milpitas, CA	SEMI-hosted medtech gathering connecting semiconductor foundries, medtech OEMs and clinical stakeholders to accelerate sensors, chips and connected-device commercialization.
Sep. 8-10, 2026	CTA Health Week / Health AI Plus 2026	Washington, DC	Digital health and AI policy convening for healthcare, technology, government and academia, including Health AI Plus on September 9 and a congressional briefing on AI in care delivery.